Novartis Focalin XR Extended-Release ADHD Therapy Will Launch In June
This article was originally published in The Pink Sheet Daily
Executive Summary
The May 26 Focalin XR approval marks Novartis’ first ADHD treatment indication in adults. The NDA was supported by two clinical trials, one in adults and one in children.
You may also be interested in...
Teva Generic Versions Of Focalin Clear FDA With 180-Day Exclusivity
The approval includes 2.5 mg, 5 mg and 10 mg formulations of dexmethylphenidate tabs for ADHD.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.